Meeting NewsVideo

VIDEO: Risuteganib meets primary outcome in phase 2 study for intermediate, dry AMD

CHICAGO — At the American Society of Retina Specialists meeting, Peter K. Kaiser, MD, of the Cole Eye Institute at the Cleveland Clinic, discusses phase 2 study results of risuteganib (Luminate, Allegro Ophthalmics), for the treatment of intermediate, dry AMD with some vision loss. The treatment met the study’s primary outcome at 28 weeks with 8 letters of visual acuity gained.

 

CHICAGO — At the American Society of Retina Specialists meeting, Peter K. Kaiser, MD, of the Cole Eye Institute at the Cleveland Clinic, discusses phase 2 study results of risuteganib (Luminate, Allegro Ophthalmics), for the treatment of intermediate, dry AMD with some vision loss. The treatment met the study’s primary outcome at 28 weeks with 8 letters of visual acuity gained.

 

    See more from ASRS 2019